Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / COMMON-STOCK
-
Shares outstanding
-
72.2M
-
Number of holders
-
142
-
Total 13F shares, excl. options
-
76.6M
-
Shares change
-
-8.6M
-
Total reported value, excl. options
-
$313M
-
Value change
-
-$53.8M
-
Put/Call ratio
-
0.11
-
Number of buys
-
79
-
Number of sells
-
-60
-
Price
-
$4.09
Significant Holders of Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) as of Q2 2024
166 filings reported holding ZNTL - Zentalis Pharmaceuticals, Inc. - COMMON-STOCK as of Q2 2024.
Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) has 142 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 76.6M shares
.
Largest 10 shareholders include Matrix Capital Management Company, LP (14M shares), FMR LLC (8.68M shares), EVENTIDE ASSET MANAGEMENT, LLC (8.55M shares), VANGUARD GROUP INC (5.65M shares), BlackRock Inc. (4.82M shares), CITADEL ADVISORS LLC (4.5M shares), Decheng Capital LLC (3.07M shares), STATE STREET CORP (3.05M shares), MORGAN STANLEY (1.95M shares), and Woodline Partners LP (1.52M shares).
This table shows the top 142 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.